CHARTER OF THE RESEARCH & DEVELOPMENT COMMITTEE OF THE BOARD OF DIRECTORS OF PROKIDNEY CORP.

EFFECTIVE APRIL 11, 2023

I. PURPOSE OF THE COMMITTEE

The purpose of the Research & Development Committee (the "Committee") of ProKidney Corp. (the "Company") is to assist the Board of Directors (the "Board") in ensuring that the research and development ("R&D") organization is optimized in terms of structure, focus and operations to support the strategic goals of the company and to provide recommendations to the Board on key strategic and tactical issues relating to the Company's R&D activities. To accomplish this purpose, the Committee reviews and monitors the science, processes and procedures, and infrastructure underlying the Company's major discovery and development programs. The Committee serves a board-level oversight role in which it provides advice, counsel and direction to management on the basis of the information it receives, discussions with management and the experience of the Committee members to guide strategic decision making.

II. COMPOSITION OF THE COMMITTEE

The Committee shall consist of no fewer than three (3) directors, one of whom shall be the CEO and one of whom shall act as chairman. Directors named to this Committee shall be among the most qualified (in terms of education and experience) to fulfill the mandates of this Charter and to review and offer relevant comment on the activities of the R&D organization of the Company. The Committee shall also include as ex-officio members the senior member of the Company's R&D organization who shall serve as Secretary and will be responsible for the preparation of the meeting agenda (in consultation with the CEO and the Committee chairman) and meeting minutes. Other members of the Company's management team and/or R&D organization, and external consultants may be invited systematically or periodically depending on agenda and Committee request.

III. RESPONSIBILITIES AND AUTHORITY OF THE COMMITTEE

Within the scope of the role of the Committee described above, the Committee is charged by the Board with the responsibility to:

• Review the science, clinical and regulatory strategy, trial design and results underlying major R&D programs

• Receive presentations and discuss the advancement/enrollment of clinical programs with critical paths identified and timelines evaluated

• Identify and review specific areas of risk, opportunity and potential problems with the Company's R&D programs

• Review medical affairs strategies, programs, and outreach initiatives of the Company

• Review the progress toward achievement of key R&D milestones and suggest/endorse actions to address issues

• Review the interactions of the R&D organization with regulatory bodies, especially regarding reporting of efficacy outcomes, adverse events and/or unexpected negative data observed in the preclinical and clinical studies conducted by the Company

• Significant correspondence with FDA, EMA and/or MHLW (PDMA) should be reviewed quarterly

• The Committee shall also have the authority to retain, as necessary, the services of one or more advisors, consultants or attorneys, which may be the Company's in-house or outside counsel, to assist the Committee in discharging its responsibilities under this Charter